No nausea or vomiting over trial period · cancer patients
Olanzapine probably leads to higher no nausea or vomiting over trial period compared with placebo/no treatment (moderate certainty).
1 finding from 1 review
RR 1.98 [1.59, 2.47]
Studies not reported
Moderate
Participant satisfaction · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient Global Impression of Change · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse events · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Somnolence/fatigue · cancer patients
It is very uncertain whether olanzapine changes somnolence/fatigue compared with NK1 antagonist (very low certainty).
1 finding from 1 review
RR 1.33 [0.4, 4.49]
Studies not reported
Very low
Serious adverse events · cancer patients
Olanzapine showed no clear difference in serious adverse events compared with placebo/no treatment (low certainty).
1 finding from 1 review
RR 2.46 [0.48, 12.55]
Studies not reported
Low
Participant preference ‐ wish to use drug in next treatment · cancer patients
Olanzapine showed no clear difference in participant preference ‐ wish to use drug in next treatment compared with placebo/no treatment (moderate certainty).
1 finding from 1 review
RR 1.43 [0.97, 2.09]
Studies not reported
Moderate
Quality of life · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient Global Impression of Change · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse events · cancer patients
Olanzapine showed no clear difference in other adverse events compared with placebo/no treatment (low certainty).
1 finding from 1 review
RR 1.71 [0.99, 2.96]
Studies not reported
Low
Somnolence/fatigue · cancer patients
Olanzapine probably leads to higher somnolence/fatigue compared with placebo/no treatment (moderate certainty).
1 finding from 1 review
RR 2.33 [1.3, 4.18]
Studies not reported
Moderate
No nausea or vomiting over trial period · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · cancer patients
It is very uncertain whether olanzapine changes serious adverse events compared with NK1 antagonist (very low certainty).
1 finding from 1 review
RR 0.33 [0.02, 7.32]
Studies not reported
Very low
Symptoms of delirium within 24 hoursa · terminally ill adults with delirium
It is very uncertain whether summary of findings: haloperidol changes symptoms of delirium within 24 hoursa compared with olanzapine (very low certainty).
1 finding from 1 review
Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium
It is very uncertain whether summary of findings: haloperidol changes symptoms of delirium between 24 and 48 hoursa compared with olanzapine (very low certainty).
1 finding from 1 review
Specific behaviour ‐ agitation · terminally ill adults with delirium
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events including extrapyramidal effects · terminally ill adults with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found